Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.

Clinical colorectal cancer - 1 May 2005

Mehra Ranee, Murren John, Chung Gina, Smith Brian, Psyrri Amanda

Abstract excerpt

Irinotecan is an analogue of camptothecin, a topoisomerase I inhibitor, that has an important role in the management of advanced colorectal cancer. It is approved as first-line therapy in combination with 5-fluorouracil and leucovorin or as monotherapy in the second-line setting. Its clinical use has been associated with variability in terms of pharmacokinetic behavior and toxicities, especially myelosuppression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diarrhea

Share to Glucuronosyltransferase

Share to Hyperbilirubinemia

Share to Irinotecan

Share to Neutropenia

Share to Pharmacogenetics

Source

Identifiers

PMID: 15929808
DOI: 10.3816/ccc.2005.n.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.PMID 15929808Read ↗

Pharmacogenetics of Irinotecan Disposition and Toxicity: A ReviewSemantic proximity Read ↗

Pharmacogenetics and irinotecan therapy.Semantic proximity Read ↗

Insights, challenges, and future directions in irinogenetics.Semantic proximity Read ↗

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.Semantic proximity Read ↗

UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?Semantic proximity Read ↗

An overview of the recent progress in irinotecan pharmacogenetics.Semantic proximity Read ↗

Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.Semantic proximity Read ↗

Clinical Pharmacogenetics of Irinotecan (CPT-11)Semantic proximity Read ↗

Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.Semantic proximity Read ↗

Pharmacogenetics of irinotecan toxicitySemantic proximity Read ↗

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.Semantic proximity Read ↗

Pharmacogenetics of IrinotecanSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.